Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
7Customers
3Debt Items
5Related Chains
Source-Backed Evidence Depth
Tandem Diabetes Care, Inc. (TNDM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
2Distinct source URLs
6High confidence
0.751Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Tandem Diabetes Care, Inc. Suppliers
Ticker
Name
Confidence
Evidence
UNOMEDICAL-A-S
UNOMEDICAL-A-S
92%
We purchase all of our currently marketed infusion sets from a third-party supplier, Unomedical A/S, a subsidiary of the ConvaTec Group.
AMF-MEDICAL
AMF-MEDICAL
90%
In January 2025, the Company entered into an amendment agreement with AMF Medical that removed contingent liabilities included in the original share purchase agreement entered into in 2022.
Tandem Diabetes Care, Inc. Customers
Ticker
Name
Confidence
Evidence
BSI-GROUP
BSI-GROUP
62%
channels so our customers’ orders can be serviced. While we have been working to increase our sales in the United States through our direct third-party payor contracts, the percentage is currently le…
CAPILLARY-BIOMEDICAL-INC
CAPILLARY-BIOMEDICAL-INC
62%
in-process research and development assets with no alternative future use, and acquisition related expenses, on its consolidated statements of operations in acquired in-process research and developme…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
attributable to state and foreign income tax expense as a result of current taxable income in certain jurisdictions. 28 Liquidity and Capital Resources As of March 31, 2026, we had $570.3 million in …
CONVATEC-GROUP
CONVATEC-GROUP
62%
channels so our customers’ orders can be serviced. While we have been working to increase our sales in the United States through our direct third-party payor contracts, the percentage is currently le…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
may face criticism regarding the accuracy, adequacy, or completeness of our disclosures. Statements about our ESG initiatives, goals, and progress may rely on evolving measurement standards, developi…
F-HOFFMAN-LA-ROCHE-AG
F-HOFFMAN-LA-ROCHE-AG
62%
in-process research and development assets with no alternative future use, and acquisition related expenses, on its consolidated statements of operations in acquired in-process research and developme…
ROCHE-DIABETES-CARE-GMBH
ROCHE-DIABETES-CARE-GMBH
62%
in-process research and development assets with no alternative future use, and acquisition related expenses, on its consolidated statements of operations in acquired in-process research and developme…
Tandem Diabetes Care, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TNDM-DEBT-13035
Warrants outstanding: 73.73
90%
xbrl warrant detail from xbrl 2024-12-31.
TNDM-DEBT-13036
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
TNDM-DEBT
Debt stack $643.2M
90%
Market cache reports total debt of $643.2M.
Tandem Diabetes Care, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Tandem Diabetes Care, Inc..
Tandem Diabetes Care, Inc. Ownership
Holder
Name
Confidence
Evidence
TNDM-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 277 tracked holders.
Tandem Diabetes Care, Inc. Extended Supply Chain Network
